Yahya Kharbat

Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting ~7.2 million Americans aged 65 and older, with projections reaching 12.7 million by 2050 and annual care costs exceeding $360 billion.¹ The disease is defined by two pathological hallmarks: amyloid-beta (Aβ) plaques and neurofibrillary tau tangles. Among toxic amyloid species, soluble Aβ42 oligomers (Aβ42o) are recognized as the primary drivers of neurodegeneration, operating through oxidative stress, mitochondrial dysfunction, tau propagation, and neuroinflammation. Current treatments — cholinesterase inhibitors, memantine, and anti-amyloid monoclonal antibodies (lecanemab, donanemab) — provide only modest symptomatic benefit and do not prevent or reverse the downstream neuronal damage caused by Aβ42o. A 2026 Cochrane meta-analysis of 17 RCTs (n = 20,342) found anti-amyloid antibodies produced a “trivial” cognitive effect (ADAS-Cog SMD −0.11) while significantly increasing amyloid-related imaging abnormalities (ARIA),² underscoring the need for a multi-target neuroprotective strategy capable of reaching the brain non-invasively.

Objective: This narrative review examines the mechanistic basis of Aβ42o-driven neurodegeneration and evaluates preclinical evidence for extracellular vesicles derived from hiPSC-differentiated neural stem cells (hiPSC-NSC-EVs) as a multi-target, cell-free neuroprotective therapy for AD.

Search Methods: A PubMed literature search (2017–2025), used MeSH terms and keywords including: “Alzheimer’s disease,” “amyloid-beta oligomers,” “extracellular vesicles,” “neural stem cells,” “induced pluripotent stem cells,” “neuroprotection,” “neuroinflammation,” “CAMKK2-AMPK,” “tau oligomers,” “intranasal drug delivery,” and “mitochondrial dysfunction.”

Results: Two critical pathways underlie Aβ42o-initiated neurodegeneration. Lee et al. demonstrated that Aβ42o overactivate the CAMKK2-AMPK kinase pathway in cortical and hippocampal neurons, driving excessive mitochondrial fission (via MFF) and mitophagy (via ULK2), depleting dendrites of mitochondria and eliminating excitatory synapses—the earliest structural correlate of cognitive decline.³ Kadamangudi et al. further showed that Aβ42o enhance tau oligomer binding and internalization at human synapses using post-mortem AD synaptosomes, demonstrating active promotion of trans-synaptic tau propagation through synaptic endocytic machinery.⁴ Together, these findings establish that Aβ42o simultaneously destroy synapses and spread tau pathology.

Rao et al. provided direct in vitro evidence that hiPSC-NSC-EVs protect human neurons against these effects: EV treatment of neurons exposed to 1 µM Aβ42o significantly reduced neuronal death, reactive oxygen species, and pathological tau phosphorylation while restoring mitochondrial membrane potential and autophagy flux—results replicated across two independent hiPSC lines.⁵ Upadhya et al. identified pentraxin-3 (PTX3) and miR-21-5p as key anti-inflammatory cargo, showing EV treatment significantly reduced TNF-α and IL-1β secretion from activated human iMicroglia without impairing microglial Aβ phagocytosis.⁶ Finally, Attaluri et al. demonstrated that a single intranasal dose of 25×10⁹ PKH26-labeled hiPSC-NSC-EVs achieved brain-wide distribution in 5xFAD mice within 45 minutes, with uptake confirmed in neurons, microglia, astrocytes, and oligodendrocytes, establishing a feasible non-invasive delivery route that bypasses the blood-brain barrier, though functional efficacy at these distribution sites remains to be confirmed.⁷

Conclusion: hiPSC-NSC-EVs represent a promising multi-target, cell-free therapeutic platform for AD that simultaneously addresses mitochondrial dysfunction, synaptic vulnerability, tau propagation, neuroinflammation, and oxidative stress. Unlike anti-amyloid antibodies, they act downstream of amyloid to protect neurons already subjected to oligomer-mediated injury, without reported ARIA risk. Notably, in vivo cognitive and synaptic efficacy data remain absent, representing the most critical gap before clinical translation. Next steps include in vivo efficacy studies in AD mouse models, cargo optimization (PTX3 and miR-21-5p content), and development of a scalable cGMP manufacturing pipeline toward IND-enabling studies.

Works Cited

1. 2024 Alzheimer’s disease facts and figures. Alzheimers Dement. 2024;20:3708–3821. doi:10.1002/alz.13809
2. Nonino F, Minozzi S, Sambati L, et al. Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2026;4(4):CD016297. doi:10.1002/14651858.CD016297
3. Lee A, Kondapalli C, Virga DM, et al. Aβ42 oligomers trigger synaptic loss through CAMKK2-AMPK-dependent effectors coordinating mitochondrial fission and mitophagy. Nat Commun. 2022;13(1):4444. doi:10.1038/s41467-022-32130-5
4. Kadamangudi S, Marcatti M, Zhang WR, et al. Amyloid-β oligomers increase the binding and internalization of tau oligomers in human synapses. Acta Neuropathol. 2024;149(1):2. doi:10.1007/s00401-024-02839-2
5. Rao S, Madhu LN, Babu RS, et al. Extracellular vesicles from hiPSC-derived NSCs protect human neurons against Aβ-42 oligomers induced neurodegeneration, mitochondrial dysfunction and tau phosphorylation. Stem Cell Res Ther. 2025;16(1):191. doi:10.1186/s13287-025-04324-3
6. Upadhya R, Madhu LN, Rao S, Shetty AK. Proficiency of extracellular vesicles from hiPSC-derived neural stem cells in modulating proinflammatory human microglia: role of pentraxin-3 and miRNA-21-5p. Front Mol Neurosci. 2022;15:845542. doi:10.3389/fnmol.2022.845542
7. Attaluri S, Jaimes Gonzalez J, Kirmani M, et al. Intranasally administered extracellular vesicles from human induced pluripotent stem cell-derived neural stem cells quickly incorporate into neurons and microglia in 5xFAD mice. Front Aging Neurosci. 2023;15:1200445. doi:10.3389/fnagi.2023.1200445